<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03712449</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-MA-FAS-0579</org_study_id>
    <nct_id>NCT03712449</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Subject Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment</brief_title>
  <official_title>Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to quantify the psychological and emotional impact of
      comprehensive aesthetic treatment with a portfolio of Allergan products by measuring the
      change in subject's satisfaction with facial appearance from baseline to the final study
      visit.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline before treatment in the Rasch-transformed score of the FACE-Q Satisfaction with facial appearance overall scale.</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in subject's assessment of expectations of life in Rasch-transformed score of the FACE-Q expectation scale aging appraisal</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mean change from baseline in subject's assessment of age-related facial appearance in Rasch-transformed score of the FACE-Q</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in subject's assessment of psychological well-being in Rasch-transformed score of the FACE-Q psychological function scale</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in subject's assessment of social function in the Rasch-transformed score of the FACE-Q social function scale.</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change subject's assessment of overall satisfaction with skin in Rasch-transformed score of FACE-Q satisfaction with skin</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in responders achieving a younger category in subject's assessment of age-related facial appearance measured by self-perception of age</measure>
    <time_frame>Baseline, Week 11</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Facial Rhytides, Skin Folds, Loss of Volume and Skin Quality</condition>
  <arm_group>
    <arm_group_label>Juvéderm, BOTOX, BELKYRA, and SkinMedica</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BELKYRA may be administered by injections at least 1 month apart for up to 6 treatments from V1 to V6.
From V7to V9, the subject will begin Facial filler injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study At V10 an 11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JUVÉDERM®</intervention_name>
    <description>Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)</description>
    <arm_group_label>Juvéderm, BOTOX, BELKYRA, and SkinMedica</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOTOX Cosmetic®</intervention_name>
    <description>Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)</description>
    <arm_group_label>Juvéderm, BOTOX, BELKYRA, and SkinMedica</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BELKYRA®</intervention_name>
    <description>Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)</description>
    <arm_group_label>Juvéderm, BOTOX, BELKYRA, and SkinMedica</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SkinMedica</intervention_name>
    <description>Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)</description>
    <arm_group_label>Juvéderm, BOTOX, BELKYRA, and SkinMedica</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Accept the obligation not to receive any other facial procedures or treatments at any
             time during the study that are not related to the study

          -  Women of childbearing potential must have a negative urine pregnancy test before each
             injectable treatment and practice a reliable method of contraception throughout the
             study

          -  Willing to avoid direct and prolonged sun exposure to the facial skin, which includes
             tanning beds, for the duration of the study

        Exclusion Criteria:

          -  History of any intervention to treat SMF (e.g. liposuction, surgery, or lipolytic
             agents)

          -  History of trauma associated with the chin or neck areas that in the judgment of the
             investigator may affect evaluation of safety or efficacy of treatment

          -  An anatomical feature (e.g. predominant subplatysmal fat, loose skin in the neck or
             chin area, prominent platysmal bands) for which reduction in SMF may, in the judgment
             of the investigator, result in an aesthetically unacceptable outcome.

          -  Evidence of any cause of enlargement in the submental area (e.g. thyroid enlargement,
             cervical adenopathy, ptotic submandibular gland) other than localized SMF

          -  Any medical condition (e.g. respiratory, cardiovascular, hepatic, neurological
             disease, or thyroid dysfunction) that would interfere with assessment of safety or
             efficacy or compromise the subject's ability to undergo study procedures or give
             informed consent

          -  Body mass index (BMI) &gt; 30

          -  Known allergy or sensitivity to the study products or their components

          -  Pregnant, lactating, or planning to become pregnant at any time during the study

          -  Received BOTOX Cosmetic or treatment with any other botulinum toxin product for any
             condition at any time prior to entry in the study

          -  Received (or is planning to receive) anticoagulation, antiplatelet or thrombolytic
             medications (e.g. warfarin) or other substances known to increase coagulation time
             from 10 days prior to injection and up to 3 days post-injection

          -  Undergone plastic surgery of the face and/or neck, tissue grafting, or tissue
             augmentation with silicone, fat, or other permanent dermal fillers, or be planning to
             undergo any of these procedures at any time during the study

          -  Received temporary or semi-permanent facial or neck dermal filler injections (e.g. HA,
             calcium hydroxylapatite, L-polylactic acid) at any time prior to entry in the study

          -  Received mesotherapy, skin resurfacing (laser, photomodulation, intense pulsed light,
             radio frequency, dermabrasion, chemical peel, or non-ablative procedures) in the face
             or neck within 6 months prior to study enrollment

          -  Began use of any new over-the-counter (OTC) or prescription, oral or topical,
             antiwrinkle products on the facial area within 90 days prior to enrollment or planning
             to begin use of such products at any time during the study

          -  Lip tattoos, facial hair or scars that would interfere with visualization of the lips
             and perioral area for the effectiveness assessments

          -  Received any investigational product within 60 days prior to study enrollment or
             planning to participate in another investigation during the course of this study

          -  An employee (or a relative of an employee) of the investigators, Allergan, or
             representative of Allergan

          -  Current use of oral corticosteroids

          -  Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. aspirin, ibuprofen)
             with the exception of a daily low dose of aspirin, from 10 days prior to injection up
             to 3 days post-injection

          -  Prescription topical retinoid therapy and/or topical hormone cream applied to the
             face, for potential subjects who have not been on a consistent dose regimen for at
             least 6 months prior to enrollment and who are unable to maintain regimen for the
             study

          -  Systemic retinoid therapy within one year prior to study enrollment

          -  Medical condition that may increase the risk of exposure to botulinum toxin including
             diagnosed myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis, or
             any other disease that might interfere with neuromuscular function

          -  Current use of aminoglycoside antibiotics, curare-like agents, or agents that might
             interfere with neuromuscular (skeletal) function

          -  History of facial nerve palsy

          -  Anticipated need for treatment with botulinum toxin of any serotype for any reason
             during the study (other than study treatment)

          -  Tendency to accumulate fluid in the lower eyelids, or large infraorbital fat pads,
             i.e. significant convexity or projection from the infraorbital fat pads

          -  Mid-face volume deficit due to congenital defect, trauma, abnormalities in adipose
             tissue related to immune-mediated diseases such as generalized lipodystrophy (e.g.
             juvenile dermatomyositis), partial lipodystrophy (e.g. Barraquer-Simons syndrome),
             inherited disease, or human immunodeficiency virus-related disease

          -  Undergone oral surgery or other dental procedures (e.g. tooth extraction, orthodontia,
             or implantation) within 30 days prior to enrollment or be planning to undergo any of
             these procedures during the study

          -  Subjects with neuromuscular disorders including generalized muscle weakness, diplopia,
             ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise

          -  Subjects with a history of allergies or hypersensitivity to HA or lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Sangha</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carruthers &amp; Humphrey Cosmetic Dermatology</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V5Z 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Skin MD Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V6H 1K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Derm</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V6H 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermetics</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>ON L7N 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Nowell Solish</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M5R 3N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bertucci MedSpa</name>
      <address>
        <city>Woodbridge</city>
        <state>Ontario</state>
        <zip>ON L4L 8E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.allerganclinicaltrials.com/</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

